BATS:ARKG ARK Genomic Revolution ETF (ARKG) Price, Holdings, & News $23.85 +0.24 (+1.02%) As of 11:30 AM Eastern This is a fair market value price provided by Polygon.io. Learn more. Add Compare Share Share Stock Analysis Stock AnalysisChartHeadlinesHoldingsOwnershipRatingsBuy This Stock About ARK Genomic Revolution ETF (BATS:ARKG) 30 days 90 days 365 days Advanced Chart View Price History Chart DataSkip Price History Chart Get ARKG alerts:Sign Up Key Stats Today's Range$24.20▼$25.2450-Day Range$22.12▼$26.5652-Week Range$17.51▼$31.16Volume4.90 million shsAverage Volume2.73 million shsMarket Capitalization$1.07 billionAssets Under Management$989.97 millionDividend YieldN/ANet Expense Ratio0.75%Aggregate RatingModerate Buy ETF Overview The ARK Genomic Revolution ETF (ARKG) is an exchange-traded fund that mostly invests in stocks based on a particular theme. The fund is an actively managed fund that targets companies involved in the genomics industry. ARKG was launched on Oct 31, 2014 and is managed by ARK. Read More ARK Genomic Revolution ETF ExpensesTypeARKGTheme ETFsEquity ETFsBATS ETFsAll ETFsManagement Fee0.75%0.57%0.56%0.57%0.53%Other Expenses0.00%0.57%0.56%0.48%0.56%Total Expense0.75%0.74%0.76%0.71%0.73%Fee Waiver0.00%-0.76%-0.66%-0.46%-0.63%Net Expense0.75%0.60%0.63%0.64%0.60% Receive ARKG Stock News and Ratings via Email Sign-up to receive the latest news and ratings for ARK Genomic Revolution ETF and its competitors with MarketBeat's FREE daily newsletter. Email Address ARKG ETF News HeadlinesWhy Cathie Wood Is Loading Up on This Hot Growth Stock (And Should You?)July 25, 2025 | finance.yahoo.comARKG: April's Wash-Out Low Is Encouraging, Healthcare Still SoftJuly 25, 2025 | seekingalpha.comHIDDEN IN THE BOOK OF GENESIS…“This land I will give to you…” — a 4,000-year-old line from Genesis may hold the key to unlocking a $150 trillion vault of untapped American wealth. Former CIA advisor Jim Rickards calls it the “Old Testament Wealth Code” — and says it could transform your financial future. He’s revealing everything in a new presentation.August 12 at 2:00 AM | Paradigm Press (Ad)ARK Genomic Revolution ETF (ARKG) - Yahoo FinanceJuly 11, 2025 | finance.yahoo.comCathie Wood shells out $13.9 million for one high-stakes biotech stockJuly 8, 2025 | msn.comARK Genomic Revolution ETF (ARKG) Risk - Yahoo FinanceJuly 3, 2025 | finance.yahoo.comSee More Headlines ARKG ETF - Frequently Asked Questions How have ARKG shares performed this year? ARK Genomic Revolution ETF's stock was trading at $23.5450 on January 1st, 2025. Since then, ARKG shares have decreased by 0.7% and is now trading at $23.3810. Who are ARK Genomic Revolution ETF's major shareholders? ARK Genomic Revolution ETF's top institutional investors include Kingstone Capital Partners Texas LLC (0.35%), Prudential PLC (0.31%), Cetera Investment Advisers (0.21%) and Bank of Montreal Can (0.15%). How do I buy shares of ARK Genomic Revolution ETF? Shares of ARKG stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. What other stocks do shareholders of ARK Genomic Revolution ETF own? Based on aggregate information from My MarketBeat watchlists, some other companies that ARK Genomic Revolution ETF investors own include Invesco QQQ (QQQ), ARK Innovation ETF (ARKK), Tesla (TSLA), NVIDIA (NVDA), Meta Platforms (META), AbbVie (ABBV) and PayPal (PYPL). Fund Details IssuerARK Fund NameARK Genomic Revolution ETF Tax ClassificationRegulated Investment Company Stock ExchangeBATSCurrent SymbolBATS:ARKG Inception Date10/31/2014 Fund ManagerCatherine Wood WebN/A PhoneN/AFund Focus Asset ClassEquity BenchmarkN/A CategoryStrategy FocusTheme Development LevelBlended Development RegionGlobal Number of Holdings38 Fund Statistics Assets Under Management$989.80 million Average Daily Volume$2.43 million Discount/Premium0.01% Administrator, Advisor and Custodian AdministratorThe Bank of New York Mellon Corporation AdvisorARK Investment Management, LLC CustodianThe Bank of New York Mellon Corporation DistributorForeside Fund Services, LLC Transfer AgentThe Bank of New York Mellon Corporation TrusteeN/A Lead Market MakerJane Street Options OptionableOptionable Options Volume2,491 Put Options559 Call Options1,932 Miscellaneous Outstanding Shares44,700,000Beta1.62 Creation Unit50,000 Creation Fee$500.00 Analysts Agree—These Gold Picks Outshine the RestUnlock the timeless value of gold with our exclusive 2025 Gold Forecasting Report. Explore why gold remains the ultimate investment for safeguarding wealth against inflation, economic shifts, and global uncertainties. Whether you're planning for future generations or seeking a reliable asset in turbulent times, this report is your essential guide to making informed decisions.Get This Free Report Top 10 ARKG HoldingsCRISPR Therapeutics (NASDAQ:CRSP)Holding Weight: 11.04%Tempus AI (NASDAQ:TEM)Holding Weight: 9.23%Twist Bioscience (NASDAQ:TWST)Holding Weight: 7.30%Recursion Pharmaceuticals (NASDAQ:RXRX)Holding Weight: 6.15%Guardant Health (NASDAQ:GH)Holding Weight: 5.72%Natera (NASDAQ:NTRA)Holding Weight: 4.59%Personalis (NASDAQ:PSNL)Holding Weight: 4.39%Schrodinger (NASDAQ:SDGR)Holding Weight: 4.04%Beam Therapeutics (NASDAQ:BEAM)Holding Weight: 4.03%10x Genomics (NASDAQ:TXG)Holding Weight: 3.93%Full Holdings DetailsARKG Sector ExposureARKG Industry Exposure This page (BATS:ARKG) was last updated on 8/12/2025 by MarketBeat.com Staff From Our PartnersWhen the levee breaksThe U.S. Treasury just confirmed it plans to borrow $1.01 trillion this quarter—nearly double what was project...Porter & Company | SponsoredThe stealth altcoin the financial world is underestimatingThe Single Most Undervalued DeFi Protocol You've Never Heard Of If there's one cryptocurrency you should b...Crypto 101 Media | SponsoredMy shocking meeting in Washington, D.C.After a shocking discovery in D.C., Jeff Brown is revealing: President Trump’s “Project MAFA” Get a look...Brownstone Research | SponsoredBig Changes Coming in August — Is Your IRA Ready?Banks aren’t waiting for the headlines to catch up. They’ve already started moving their wealth out of pape...Reagan Gold Group | Sponsored#1 Pre-IPO Opportunity For 2025 [Take Action Now!]James Altucher has scored 37X and even 60X returns on past pre-IPO deals. But now he says a much bigger opport...Paradigm Press | SponsoredSilver Demand Is Exploding—and Supply Can’t Keep UpElon's Next Market Move Could Send Silver Soaring Every industry Elon Musk touches explodes—from Tesla to S...Priority Gold | SponsoredMarket Crash Warning: How to Protect Your Wealth Before August 12thChina tariffs hit August 12—and experts warn a market meltdown may follow. A free guide from American Alter...American Alternative | SponsoredMan Who Called Nvidia at $1.10 Says Buy This Now...In 2004, one man called Nvidia before just about anyone knew it existed. Now, this same guy says a new comp...The Oxford Club | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding ARK Genomic Revolution ETF Please log in to your account or sign up in order to add this asset to your watchlist. Share ARK Genomic Revolution ETF With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
MarketBeat All Access